Dibase calcium phosphate

(&plusmn)12(13)-EpOME-d4 contains four deuterium atoms at the 9, 10, 12, and 13 positions. It is intended for use as an internal standard for the quantification of latanoprost by GC- or LC-MS.

DescriptionAir- and moisture-tolerant, this (+)-PSI Reagent was developed in theBaran lab for stereocontrolled synthesis of phosphorothioate oligonucleotides. The enantiomer, (−)-PSI Reagent, is also available (cat#ALD00602).The PSI Reagents open

DescriptionAir- and moisture-tolerant, this (+)-PSI Reagent was developed in theBaran lab for stereocontrolled synthesis of phosphorothioate oligonucleotides. The enantiomer, (−)-PSI Reagent, is also available (cat#ALD00602).The PSI Reagents open

DescriptionAir- and moisture-tolerant, this (+)-PSI Reagent was developed in theBaran lab for stereocontrolled synthesis of phosphorothioate oligonucleotides. The enantiomer, (−)-PSI Reagent, is also available (cat#ALD00602).The PSI Reagents open

(+)-SHIN1 ((+)-RZ-2994) is an active (+) enantiomer of SHIN1.In Vitro(+)-SHIN1 ((+)-RZ-2994) is potent against cytosolic SHMT1 with an IC 50 for blocking growth of less than 50 nM and 870 nM in SHMT2 deletion cells and HCT-116 cells, respectively.

Biochem/physiol Actions Metabolite of the mevalonate pathway, which plays a key role in the biosynthesis of sterols, dolichol, heme and ubiquinone. Of interest for research in the disease areas oncology, autoimmune diseases, artherosclerosis and

(1S,2S,3R)-DT-061 is an enantiomer of DT-061 ( HY-112929 ). DT-061 is an orally active activator of protein phosphatase 2A (PP2A). (1S,2S,3R)-DT-061 can be used as a negative control in the research of KRAS-mutant and MYC-driven lung cancer

Description(24R)-24,25-Dihydroxyvitamin D3or secalciferol is produced in kidney. It is the one of the most active form of vitamin D and an essential circulating vitamin D3metabolite.(24R)-24,25-Dihydroxyvitamin D3has been used to assess its

LPA is a potent lipid mediator that elicits its effect through four distinct receptors - LPA1/EDG-2, LPA2/EDG-4, LPA3/EDG-7 and LPA4/GPR23.{11049,13009} OMPT is a selective agonist of the LPA3 receptor.

LPA is a potent lipid mediator that elicits its effect through four distinct receptors - LPA1/EDG-2, LPA2/EDG-4, LPA3/EDG-7 and LPA4/GPR23.{11049,13009} OMPT is a selective agonist of the LPA3 receptor.

LPA is a potent lipid mediator that elicits its effect through four distinct receptors - LPA1/EDG-2, LPA2/EDG-4, LPA3/EDG-7 and LPA4/GPR23.{11049,13009} OMPT is a selective agonist of the LPA3 receptor.

LPA is a potent lipid mediator that elicits its effect through four distinct receptors - LPA1/EDG-2, LPA2/EDG-4, LPA3/EDG-7 and LPA4/GPR23.{11049,13009} OMPT is a selective agonist of the LPA3 receptor.